Connection

Kim Payne to Precursor Cell Lymphoblastic Leukemia-Lymphoma

This is a "connection" page, showing publications Kim Payne has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
  1. Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog. 2011; 16(1-2):3-12.
    View in: PubMed
    Score: 0.343
  2. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia. Leukemia. 2021 05; 35(5):1267-1278.
    View in: PubMed
    Score: 0.172
  3. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020 09 24; 136(13):1520-1534.
    View in: PubMed
    Score: 0.168
  4. The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020 Mar 22; 21(6).
    View in: PubMed
    Score: 0.162
  5. Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity. Leukemia. 2019 11; 33(11):2720-2731.
    View in: PubMed
    Score: 0.153
  6. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. 2016 Aug 02; 7(31):49722-49732.
    View in: PubMed
    Score: 0.126
  7. Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget. 2016 Jul 19; 7(29):46014-46027.
    View in: PubMed
    Score: 0.126
  8. Cell cycle-specific function of Ikaros in human leukemia. Pediatr Blood Cancer. 2012 Jul 15; 59(1):69-76.
    View in: PubMed
    Score: 0.091
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.